KIORA PHARMACEUTICALS, INC. Comprehensive Income
KIORA PHARMACEUTICALS, INC. (KPRX) reported Comprehensive Income of -$13.34 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-23.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2017-02-23
- KIORA PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2016-12-31 was -$3.70M.
- KIORA PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2016-09-30 was -$3.38M.
- KIORA PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2016-06-30 was -$3.82M.
- KIORA PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2016-03-31 was -$2.44M.
- KIORA PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2016 was -$13.34M.
- KIORA PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2015 was -$8.27M.
- KIORA PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2014 was -$1.77M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2016-12-31 | -$3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$7.07M derived: sum of 2 quarters · filed 2017-02-23 | -$10.90M derived: sum of 3 quarters · filed 2017-02-23 | -$13.34M 10-K · filed 2017-02-23 |
| 2016-09-30 | -$3.38M 10-Q · filed 2016-11-01 | -$7.20M derived: sum of 2 quarters · filed 2016-11-01 | -$9.64M 10-Q · filed 2016-11-01 | -$12.32M derived: sum of 4 quarters · filed 2017-02-23 |
| 2016-06-30 | -$3.82M 10-Q · filed 2016-08-10 | -$6.27M 10-Q · filed 2016-08-10 | -$8.94M derived: sum of 3 quarters · filed 2017-02-23 | -$10.30M derived: sum of 4 quarters · filed 2017-02-23 |
| 2016-03-31 | -$2.44M 10-Q · filed 2016-05-13 | -$5.12M derived: sum of 2 quarters · filed 2017-02-23 | -$6.48M derived: sum of 3 quarters · filed 2017-02-23 | -$7.99M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-12-31 | -$2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$4.04M derived: sum of 2 quarters · filed 2017-02-23 | -$5.55M derived: sum of 3 quarters · filed 2017-02-23 | -$8.27M 10-K · filed 2017-02-23 |
| 2015-09-30 | -$1.36M 10-Q · filed 2016-11-01 | -$2.87M derived: sum of 2 quarters · filed 2016-11-01 | -$5.60M 10-Q · filed 2016-11-01 | -$6.06M derived: sum of 4 quarters · filed 2016-11-01 |
| 2015-06-30 | -$1.51M 10-Q · filed 2016-08-10 | -$4.23M 10-Q · filed 2016-08-10 | -$4.69M derived: sum of 3 quarters · filed 2016-08-10 | -$4.30M derived: sum of 4 quarters · filed 2016-08-10 |
| 2015-03-31 | -$2.72M 10-Q · filed 2016-05-13 | -$3.18M derived: sum of 2 quarters · filed 2016-05-13 | -$2.79M derived: sum of 3 quarters · filed 2016-05-13 | -$3.53M derived: sum of 4 quarters · filed 2016-05-13 |
| 2014-12-31 | -$460.83K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$67.08K derived: sum of 2 quarters · filed 2016-03-30 | -$810.71K derived: sum of 3 quarters · filed 2016-03-30 | -$1.77M 10-K · filed 2016-03-30 |
| 2014-09-30 | $393.75K 10-Q · filed 2015-11-12 | -$349.88K derived: sum of 2 quarters · filed 2015-11-12 | -$1.31M 10-Q · filed 2015-11-12 | |
| 2014-06-30 | -$743.63K 10-Q · filed 2015-08-12 | -$1.70M 10-Q · filed 2015-08-12 | ||
| 2014-03-31 | -$959.66K 10-Q · filed 2015-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |